Imipenem

Especificaciones

64221-86-9Número CAS

264-734-5Número CE

(5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acidNombre IUPAC

C12H17N3O4SFórmula química

299.35 g/molPeso molecular

imipenem; 64221-86-9; Imipemide; N-Formimidoylthienamycin; Imipenem anhydrous; Imipenemum; N-formimidoyl thienamycin; (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; DTXSID2023143; MK 0787; CHEBI:471744; Anhydrous Imipenem; Imipenem, Anhydrous; MK-0787; Q20IM7HE75; (5R,6S)-6-((R)-1-Hydroxyethyl)-3-(2-(iminomethylamino)ethylthio)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carbonsaeure; (5R,6S)-3-((2-(Formimidoylamino)ethyl)thio)-6-((R)-1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid; DTXCID903143; MK0787; NSC-759901; (5R,6S)-3-(2-Formimidoylamino-ethylsulfanyl)-6-((R)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; RECARBRIO COMPONENT IMIPENEM; (5R,6S)-3-((2-((E)-(aminomethylidene)amino)ethyl)sulfanyl)-6-((1R)-1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid; (5R,6S)-3-({2-[(E)-(aminomethylidene)amino]ethyl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-3-(2-(aminomethylideneamino)ethylsulfanyl)-6-((1R)-1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid; (5R,6S)-3-(2-Formimidoylamino-ethylsulfanyl)-6-((R)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo(3.2.0)hept-2-ene-2-carboxylic acid; Anhydrous, Imipenem; N Formimidoylthienamycin; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, monohydrate, (5R-(5alpha,6alpha(R*)))-; RefChem:790833; (5R,6S)-3-(2-(aminomethylideneazaniumyl)ethylsulfanyl)-6-((1R)-1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylate; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R-(5alpha,6alpha(R*)))-; 264-734-5; 71OTZ9ZE0A; Imipenem monohydrate (h2o); Imipenem, N-Formimidoyl thienamycin; Imipenem (INN); Imipenem [INN]; CHEMBL148; 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,6-[(1R)-1-hydroxyethyl]-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-,(5R,6S)-; Imipenen; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-[(2-methanimidamidoethyl)sulfanyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-3-((2-formimidamidoethyl)thio)-6-((R)-1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Imipenemum [Latin]; CAS-64221-86-9; SR-05000000294; imipen; UNII-Q20IM7HE75; Imipenem CRS; NCGC00016928-01; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-(2-methanimidamidoethylsulfanyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1R)-1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R,6S)-; 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-, (5R,6S)-; Prestwick_844; EINECS 264-734-5; MFCD00864955; MK-787; Imipenem (anhydrous); IMIPENEM [MI]; IMIPENEM ANHYDRATE; Prestwick0_000519; Prestwick1_000519; Prestwick2_000519; Prestwick3_000519; Epitope ID:120384; IMIPENEM [WHO-DD]; BSPBio_000477; BIDD:GT0686; SPBio_002398; BPBio1_000525; orb1992144; SCHEMBL1649260; SCHEMBL2231086; SCHEMBL8781920; GTPL10821; HY-B1369A; Primaxin (imipenem + cilastatin); HMS1569H19; HMS2090A15; HMS2096H19; HMS3260H20; HMS3713H19; Pharmakon1600-01506001; Tox21_110689; Tox21_500279; BDBM50049708; BDBM50213266; EBC-26520; MSK162950; NSC759901; AKOS016010844; Tox21_110689_1; CCG-220519; CCG-221583; DB01598; LP00279; NSC-717864; SDCCGSBI-0633697.P001; NCGC00167958-01; NCGC00167958-02; NCGC00167958-03; NCGC00167958-05; NCGC00167958-09; NCGC00260964-01; (5R,6S)-3-[2-(aminomethyleneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; AS-75130; CS-0077844; NS00005888; C06665; D04515; D96091; AB01563339_01; Recarbrio (imipenem + cilastatin + relebactam).; EN300-19766283; Q425152; T124492; SR-05000000294-2; SR-05000000294-5; BRD-K23200955-002-01-5; BRD-K23200955-002-02-3; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; [5R-[5.alpha.,6.alpha.(R*)]]-6-(1-Hydroxyethyl)-3-[[2- [(iminomethyl)amino]ethyl]thio]-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid monohydrate; 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R-(5-alpha,6-alpha(R*)))-; 1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 6-(1-HYDROXYETHYL)-3-((2-((IMINOMETHYL)AMINO)ETHYL)THIO)-7-OXO-, (5R-(5.ALPHA.,6.ALPHA.(R*)))-Sinónimos